Results 11 to 20 of about 177,414 (289)
Alpha-1 Antitrypsin Augmentation Therapy
COPD: Journal of Chronic Obstructive Pulmonary Disease, 2013 The therapy of alpha-1 antitrypsin deficiency (AATD) is an example of a medical triumph over a common hereditary disease. Based on the understanding of the pathogens of the disease as a deficiency in liver production of alpha-1 antitrypsin (AAT) resulting from inherited genetic variation in both parental AAT genes, the knowledge that A1AT functions ...
Mark D Wewers
exaly +3 more sources
Memantine as an Augmentation Therapy for Anxiety Disorders
Case Reports in Psychiatry, 2012 Objective. Glutamate, an excitatory neurotransmitter in the central nervous system (CNS), may play a role in the development of anxiety. Memantine partially blocks N-methyl-D-aspartate (NMDA) receptors' glutamate channels located in the CNS.
Thomas L. Schwartz +2 more
doaj +3 more sources
Atypical antipsychotics as augmentation therapy in anorexia nervosa. [PDF]
PLoS ONE, 2015 Anorexia nervosa (AN) is a life-threatening and difficult to treat mental illness with the highest mortality rates of any psychiatric disorder. We aimed to garner preliminary data on the real-world use of olanzapine and aripiprazole as augmentation ...
Enrica Marzola +5 more
doaj +3 more sources
AAV-mediated gene augmentation therapy of CRB1 patient-derived retinal organoids restores the histological and transcriptional retinal phenotype [PDF]
Stem Cell Reports, 2023 Nanda Boon, Jan Wijnholds, Thilo M Buck
exaly +3 more sources
Cellular immunity augmentation in mainstream oncologic therapy
Cancer Biology & Medicine, 2017 Anticancer immunotherapy has undergone a long evolving journey for decades, and has been dramatically applied to mainstream treatments in oncology in recent 5 years. This progress represents an advanced milestone following cytotoxic medicine and targeted
Daohong Chen, Xiaoshi Zhang
doaj +4 more sources
Alpha-1 Antitrypsin Deficiency: Home Therapy
Frontiers in Pharmacology, 2021 While available in only a few countries, home therapy is a possible strategy for the treatment of alpha-1 antitrypsin deficiency. We want to describe our experience in the management of human alpha-1 antitrypsin using home care intravenous augmentation ...
Anna Annunziata +5 more
doaj +1 more source
COPD, 2021 Pulmonary events (PEs) associated with alpha-1 antitrypsin deficiency (AATD) can have a severe clinical course and increase healthcare resource use (HRU). However, AATD-associated HRU and healthcare costs have not been extensively described.
Ernesto Mayen Herrera +4 more
doaj +1 more source
Augmenting Exposure Therapy: Mobile Augmented Reality for Specific Phobia [PDF]
Frontiers in Virtual Reality, 2020 New technologies, such as virtual reality (VR) and augmented reality (AR), can be used as an add-on to exposure therapy for common anxiety disorders. While the benefits of VR for exposure therapy have already been demonstrated extensively in research, AR applications are only just becoming widely available.
De Witte, Nele +5 more
openaire +1 more source
Pindolol augmentation of antidepressant therapy [PDF]
British Journal of Psychiatry, 1998 BackgroundAntidepressant therapy is not always effective and is slow to take effect. In theory, these shortfalls may be caused by induction of neuronal negative feedback via pre-synaptic 5-HTIA receptors. Pindolol, an antagonist at somatodentritic pre-synaptic 5-HTIA receptors has been investigated as a potential accelerator and augmenter of ...
R, McAskill, S, Mir, D, Taylor
openaire +3 more sources
Case report: Self-administration of alpha-1 antitrypsin therapy: a report of two cases
Frontiers in Pharmacology, 2023 Intravenous augmentation therapy with human alpha-1 proteinase inhibitor for the management of respiratory disease is recommended for people with alpha-1 antitrypsin deficiency (AATD) who are nonsmokers or former smokers.
Ana M. Escribano Dueñas +3 more
doaj +1 more source